{"id":"cm336-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CM336 is an investigational monoclonal antibody in Phase 3 development from Shandong First Medical University. While the precise molecular target has not been widely disclosed in public literature, it is designed to modulate immune responses, likely through checkpoint inhibition or cytokine pathway targeting. The drug is being evaluated for oncologic and/or immunologic indications.","oneSentence":"CM336 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:28.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07409454","phase":"PHASE2","title":"MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07175493","phase":"PHASE1, PHASE2","title":"A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-11-18","conditions":"Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia","enrollment":158},{"nctId":"NCT07039578","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-07-25","conditions":"Primary Light-Chain Amyloidosis","enrollment":90},{"nctId":"NCT07181239","phase":"PHASE3","title":"Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-09","conditions":"Multiple Myeloma (MM)","enrollment":280},{"nctId":"NCT06900010","phase":"PHASE1, PHASE2","title":"A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease","status":"RECRUITING","sponsor":"Shandong First Medical University","startDate":"2025-04-01","conditions":"Autoimmune Bullous Disease","enrollment":30},{"nctId":"NCT06799611","phase":"PHASE2","title":"An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Immune Thrombocytopenia (ITP), Treatment","enrollment":20},{"nctId":"NCT05299424","phase":"PHASE1, PHASE2","title":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-08-09","conditions":"Multiple Myeloma","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CM336 Injection","genericName":"CM336 Injection","companyName":"Shandong First Medical University","companyId":"shandong-first-medical-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}